Axicabtagene ciloleucel cell suspension for infusion | China Drugs List
Public reference information, not medical advice, a prescription or an offer to supply a medicine. Confirm current approval, availability and suitability with licensed professionals.
Others
- Brand
- Yescarta
- Company
- Kite Pharma, Inc. / Gilead Sciences
- Medicine type
- Biologic
- Therapeutic area
- Oncology
- Indications recorded in the public source
- US indications cover adults with large B-cell lymphoma that resists initial chemoimmunotherapy or returns within 12 months; relapsed or refractory large B-cell lymphoma after at least two systemic treatment lines; and relapsed or refractory follicular lymphoma after at least two systemic lines. The follicular lymphoma indication has accelerated approval and requires confirmation of clinical benefit.
- Indication source and scope
- US prescribing information revised August 2026. Selected overseas indications; does not establish the Chinese approved scope.
- Prescribing-information limitations
- Overseas official prescribing information linked; a complete current Chinese label has not been verified.
- China availability status
- Chinese approval details and current availability have not been independently verified in this English-source review.
- Overseas status
- See the linked overseas regulator / manufacturer evidence. Approval and indications are jurisdiction-specific; current supply is not established.
- Insurance classification
- Not yet verified
- Insurance edition
- Chinese national insurance review pending
- Insurance verification notes
- No reimbursement determination was made for this addition; missing information is not proof of exclusion.
Sources
- https://www.gilead.com/-/media/files/pdfs/medicines/oncology/yescarta/yescarta-pi.pdf
- Yescarta — US prescribing information
Official prescribing information · US prescribing information revised August 2026
English primary source opened on 2 November 2026. The summary lists selected US indications, not the complete current Chinese approved scope.
- Source cited in the supplied price-gap report
Supplied report reference · Report dated 25 October 2026
Original report citation retained for traceability. This citation alone does not verify Chinese approval, brand identity, equivalent formulations or like-for-like prices. WAC unit and pack conversions require separate confirmation.
- Source cited in the supplied price-gap report
Supplied report reference · Report dated 25 October 2026
Original report citation retained for traceability. This citation alone does not verify Chinese approval, brand identity, equivalent formulations or like-for-like prices. WAC unit and pack conversions require separate confirmation.
- Texas DSHS — 2026 annual WAC report
Supplied report reference · Report dated 25 October 2026
Original report citation retained for traceability. This citation alone does not verify Chinese approval, brand identity, equivalent formulations or like-for-like prices. WAC unit and pack conversions require separate confirmation.
- Source cited in the supplied price-gap report
Supplied report reference · Report dated 25 October 2026
Original report citation retained for traceability. This citation alone does not verify Chinese approval, brand identity, equivalent formulations or like-for-like prices. WAC unit and pack conversions require separate confirmation.
Evidence reviewed:
Open the interactive record, public price references and discussions